Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Centre for Population Health Data at Statistics Canada, Ottawa, ON K1A 0T6, Canada.
Curr Oncol. 2022 Aug 9;29(8):5627-5643. doi: 10.3390/curroncol29080444.
The relationship between Canadian mammography screening practices for women 40−49 and breast cancer (BC) stage at diagnosis in women 40−49 and 50−59 years was assessed using data from the Canadian Cancer Registry, provincial/territorial screening practices, and screening information from the Canadian Community Health Survey. For the 2010 to 2017 period, women aged 40−49 were diagnosed with lesser relative proportions of stage I BC (35.7 vs. 45.3%; p < 0.001), but greater proportions of stage II (42.6 vs. 36.7%, p < 0.001) and III (17.3 vs. 13.1%, p < 0.001) compared to women 50−59. Stage IV was lower among women 40−49 than 50−59 (4.4% vs. 4.8%, p = 0.005). Jurisdictions with organised screening programs for women 40−49 with annual recall (screeners) were compared with those without (comparators). Women aged 40−49 in comparator jurisdictions had higher proportions of stages II (43.7% vs. 40.7%, p < 0.001), III (18.3% vs. 15.6%, p < 0.001) and IV (4.6% vs. 3.9%, p = 0.001) compared to their peers in screener jurisdictions. Based on screening practices for women aged 40−49, women aged 50−59 had higher proportions of stages II (37.2% vs. 36.0%, p = 0.003) and III (13.6% vs. 12.3%, p < 0.001) in the comparator versus screener groups. The results of this study can be used to reassess the optimum lower age for BC screening in Canada.
本研究利用加拿大癌症登记处、省级/地区筛查实践以及加拿大社区健康调查的筛查信息,评估了加拿大 40-49 岁女性的乳腺癌筛查实践与 40-49 岁和 50-59 岁女性诊断时乳腺癌分期之间的关系。在 2010 年至 2017 年期间,40-49 岁女性诊断为 I 期乳腺癌的相对比例较低(35.7% vs. 45.3%;p < 0.001),但 II 期(42.6% vs. 36.7%,p < 0.001)和 III 期(17.3% vs. 13.1%,p < 0.001)的比例较高。与 50-59 岁女性相比,40-49 岁女性 IV 期比例较低(4.4% vs. 4.8%,p = 0.005)。对 40-49 岁女性进行年度召回筛查(筛查者)的有组织筛查项目的司法管辖区与没有该项目的司法管辖区(对照组)进行了比较。在对照组司法管辖区,40-49 岁女性 II 期(43.7% vs. 40.7%,p < 0.001)、III 期(18.3% vs. 15.6%,p < 0.001)和 IV 期(4.6% vs. 3.9%,p = 0.001)的比例均高于筛查者司法管辖区的同龄人。基于 40-49 岁女性的筛查实践,50-59 岁女性在对照组和筛查者中 II 期(37.2% vs. 36.0%,p = 0.003)和 III 期(13.6% vs. 12.3%,p < 0.001)的比例更高。本研究结果可用于重新评估加拿大乳腺癌筛查的最佳较低年龄。